TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Unicycive Therapeutics ( (UNCY) ) just unveiled an announcement.
On November 14, 2025, Unicycive Therapeutics, Inc. amended its sales agreement with Guggenheim Securities, LLC to increase the potential sale of its common stock from $50 million to $100 million through an at-the-market offering. This amendment, filed with the U.S. Securities and Exchange Commission, signifies a strategic move to raise additional capital, potentially impacting the company’s financial flexibility and market positioning.
The most recent analyst rating on (UNCY) stock is a Buy with a $22.00 price target. To see the full list of analyst forecasts on Unicycive Therapeutics stock, see the UNCY Stock Forecast page.
Spark’s Take on UNCY Stock
According to Spark, TipRanks’ AI Analyst, UNCY is a Underperform.
Unicycive Therapeutics has significant financial challenges, including ongoing net losses and a reliance on debt for financing, which weigh heavily on its stock score. The technical analysis reveals a bearish trend, as the stock is trading below major moving averages. Valuation metrics further dampen the attractiveness of the stock due to negative profitability indicators. Without earnings call insights or recent corporate events to improve prospects, the overall score reflects these financial and technical weaknesses.
To see Spark’s full report on UNCY stock, click here.
More about Unicycive Therapeutics
Unicycive Therapeutics, Inc. operates in the biotechnology industry, focusing on developing and commercializing novel treatments for kidney diseases. The company is engaged in the research and development of therapeutic products aimed at addressing unmet medical needs in nephrology.
Average Trading Volume: 483,105
Technical Sentiment Signal: Sell
Current Market Cap: $90.78M
Learn more about UNCY stock on TipRanks’ Stock Analysis page.